LAUSR

Indoximod Combo Triggers Responses in Melanoma.

Sign Up to like & get
recommendations!
0 Published in 2017 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-nb2017-056

Abstract: Adding the investigational IDO-pathway inhibitor indoximod to checkpoint inhibitor therapy resulted in a 52% overall response rate in patients with advanced melanoma enrolled in a phase II trial. The combination strategy has potential as an… read more here.

Keywords: triggers responses; indoximod combo; combo triggers; responses melanoma ... See more keywords